Normative Estimates and Agreement Between 2 Measures of Health-Related Quality of Life in Older People With Frailty: Findings From the Community Ageing Research 75+ Cohort
Nikolova, S; Hulme, C; West, R; et al.Pendleton, N; Heaven, A; Bower, P; Humphrey, S; Farrin, A; Cundill, B; Lawton, R; Clegg, A
Date: 18 July 2020
Article
Journal
Value in Health
Publisher
Elsevier / International Society for Pharmacoeconomics and Outcomes Research
Publisher DOI
Abstract
Background
Previous studies have summarised evidence on health-related quality of life (HRQOL) for
older people, identifying a range of measures that have been validated, but have not sought to
present results by degree of frailty. Furthermore, previous studies did not typically use quality
of life measures that generate an overall ...
Background
Previous studies have summarised evidence on health-related quality of life (HRQOL) for
older people, identifying a range of measures that have been validated, but have not sought to
present results by degree of frailty. Furthermore, previous studies did not typically use quality
of life measures that generate an overall health utility score. Health utility scores are a
necessary component of Quality Adjusted Life Year calculations used to estimate costeffectiveness of interventions.
Methods
We calculated normative estimates in terms of mean and standard deviation for EQ-5D-5L,
SF-36 and SF-6D for a range of established frailty models. We compared response
distributions across dimensions of the measures and investigated agreement using BlandAltman and Interclass Correlation techniques.
Results
EQ-5D-5L, SF-36 and SF-6D scores decrease and their variability increases with advancing
frailty. There is strong agreement between EQ-5D-5L and SF-6D across the spectrum of
frailty. Agreement is lower for people who are most frail, indicating that different
components of the two instruments may have greater relevance for people with advancing
frailty in later life. There is a greater risk of ceiling effects using EQ-5D-5L rather than SF6D.
Conclusions.
We recommend SF-36/SF-6D as an appropriate measure of HRQOL for clinical trials if fit
older people are the planned target. In trials of interventions involving older people with
increasing frailty we recommend that both EQ-5D-5L and SF36/SF6D are included, and are
used in sensitivity analyses as part of cost-effectiveness evaluation.
Institute of Health Research
Collections of Former Colleges
Item views 0
Full item downloads 0
Except where otherwise noted, this item's licence is described as © 2020. This version is made available under the CC-BY-NC-ND 4.0 license: https://creativecommons.org/licenses/by-nc-nd/4.0/